InvestorsHub Logo
Followers 89
Posts 6862
Boards Moderated 1
Alias Born 09/18/2009

Re: cowtown jay post# 39292

Sunday, 05/14/2023 8:32:17 AM

Sunday, May 14, 2023 8:32:17 AM

Post# of 43389
Joining Stocktwits poster 'flowerchefstocks' with posts that deserve consideration are the two most recent posters, at the time of this writing, 'ChartMill,' and 'metz57.'

The value I derive from flowerchefstocks' post is in illustrating the systemic nature of Regulatory interference that I claim has been directed at us by the design of the ACTIV-5 trial. ACTIV-5 was designed to protect Big Pharma profits by keeping lenz off the market, and crushing small-cap Humanigen in the process. TX AG Paxton should be provided the list of small-cap biotech companies, in which Humanigen is included, whose value has been destroyed by Regulators, when these small companies attempt to bring covid treatments into the market.

'ChartMill's,' most recent post states there is a "Squeeze play pattern detected by our stock screener for $HGEN." I'm noting the headline only, as I didn't delve into the details. For me, there was no reason to do so. I've already noted, "...a piece of the puzzle that Dale likely placed on the table, that could be mega-significant." I see a squeeze play, too.

Finally, 'metz57' provides some commentary about the improvement noted in secondary endpoints of the ACTIV-5 trial. That's all I was looking for from the results of this trial. I have no hope that ACTIV-5 will be proven successful after peer-review, and I think it would be a waste of resources to continue to treat late-stage covid patients with lenz. The improvement noted in the secondary endpoints needs to be included in the resubmission of our EUA application based on the successful LIVE-AIR trial.

https://stocktwits.com/symbol/HGEN
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.